Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
84 hedge funds and large institutions have $455M invested in Trillium Therapeutics Inc. in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 11 closing their positions.
174% more call options, than puts
Call options by funds: $9.19M | Put options by funds: $3.35M
173% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 11
86% more capital invested
Capital invested by funds: $244M → $455M (+$211M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more funds holding
Funds holding: 65 → 84 (+19)
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.29M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$4.33M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.17M |
| 5 |
O
OrbiMed
New York
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15.2M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.55M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.3M |
| 4 |
Millennium Management
New York
|
-$6.77M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.23M |
TRIL Hedge Fund Activity: Q2 2020 in Review
84 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2020, worth a combined $455M — up 86% from $244M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TRIL positions and 11 closed out — a net gain of 19 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $15.8M. The largest seller was Deutsche Bank, cutting an estimated $15.2M.
- 84 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2020, up from 65 in Q1 2020.
- Funds reported $455M of Trillium Therapeutics Inc. stock for Q2 2020, up 86% quarter-over-quarter.
- 30 funds opened new Trillium Therapeutics Inc. positions in Q2 2020 and 11 closed out, a net change of +19 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2020 was Eventide Asset Management, an estimated $15.8M added.
- The largest Trillium Therapeutics Inc. seller in Q2 2020 was Deutsche Bank, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2020.